Abbvie Inc
NYSE:ABBV
Abbvie Inc
Total Equity
Abbvie Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$10.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$6.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
Moderna Inc
NASDAQ:MRNA
|
Total Equity
$13.9B
|
CAGR 3-Years
76%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$17.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
32%
|
CAGR 10-Years
29%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$26B
|
CAGR 3-Years
33%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
See Also
What is Abbvie Inc's Total Equity?
Total Equity
10.4B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Total Equity amounts to 10.4B USD.
What is Abbvie Inc's Total Equity growth rate?
Total Equity CAGR 10Y
9%
Over the last year, the Total Equity growth was -40%. The average annual Total Equity growth rates for Abbvie Inc have been -7% over the past three years , and 9% over the past ten years .